Clinical trial Recruiting at 1 site Observational Ages 18 and up

Analyzing non-coding RNA in patients with acute ischemic stroke

Official title: Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)

Run by Nanjing First Hospital, Nanjing Medical University · NCT04175691 · Data updated 2026-11-12

This study is trying to see if certain types of non-coding RNA in the blood can help doctors better detect and understand the outcomes of patients who have had an acute ischemic stroke.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorNanjing First Hospital, Nanjing Medical University
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedNovember 24, 2019
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 15, 2026
Trial IDNCT04175691 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 years or older who have been diagnosed with acute ischemic stroke within 72 hours of symptom onset.

Probably not a fit

Patients with a history of hemorrhagic infarction, chronic kidney or liver diseases, peripheral arterial occlusive disease, active malignant disease, or inflammatory or infectious diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the expression patterns of circular RNA (circRNA), micro-RNA (miRNA), and long non-coding RNA (lncRNA) in patients diagnosed with acute ischemic stroke compared to healthy controls. Using next-generation sequencing, the study aims to identify distinctive expression patterns of these non-coding RNAs that may serve as biomarkers for the detection and prognosis of acute ischemic stroke. The findings will be validated through quantitative real-time polymerase chain reaction (qRT-PCR) and a diagnostic model will be developed using logistic regression to assess the clinical significance of these biomarkers.

Why it matters

Potential benefit: If successful, this study could lead to the development of novel biomarkers for the early detection and prognosis of acute ischemic stroke.

How similar studies have gone: While the exploration of non-coding RNAs in stroke is a growing field, this specific approach using next-generation sequencing for acute ischemic stroke biomarkers is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 18 years or older
* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
* Within 72 hours of symptom onset
* Good performance status
* Signed an approved informed consents

Exclusion Criteria:

-a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Where it's running

  • Nanjing First Hospital, Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Best Care for Acute Stroke in General Wards

    A nurse-led program called BEST CARE ICTUS_HC is tested in hospitals without Stroke Units to see if it reduces stroke complications and helps recovery after an acute ischemic or hemorrhagic stroke.

    Recruiting University of Malaga · Antequera, Málaga and 3 other locations · NCT07627399

  • Continuous Dual Aspiration with the Zoom System for Acute Ischemic Stroke

    This trial will try using the Zoom aspiration system with a continuous dual aspiration technique to remove clots in adults with acute ischemic stroke.

    Recruiting at 25 sites Imperative Care, Inc. · Huntsville, Alabama and 24 other locations · NCT07491952

  • Dimephosphon® for recovery after acute ischemic stroke.

    This trial will test whether Dimephosphon® given 24–72 hours after stroke onset helps adults with moderate acute ischemic stroke recover better than a placebo.

    Recruiting at 5 sites Phase 3 Tatchempharmpreparaty, JSC · Vsevolozhsk, Leningradskaya Oblast' and 5 other locations · NCT07167550

  • Treatment for Acute Ischemic Stroke using DM199

    This study is testing if a new treatment called DM199 can help people with moderate acute ischemic stroke recover better when given soon after their symptoms start.

    Recruiting at 78 sites Phase 2/3 DiaMedica Therapeutics Inc · Fairhope, Alabama and 85 other locations · NCT05065216

  • Registry connecting stroke survivors with research opportunities

    This study connects stroke survivors with research opportunities to help find new treatments that can improve their recovery.

    Recruiting University of California, San Francisco · San Francisco, California · NCT03318432

  • AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

    This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

    Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.